Compare iShares Core S&P 500 ETF (IVV) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Tempus AI — how do they compare? iShares Core S&P 500 ETF trades at $780.79 (market cap $899.63B), while Tempus AI trades at $70.22 (market cap $12.77B). The key difference: iShares Core S&P 500 ETF is far larger — about 70.4× Tempus AI's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and Tempus AI for 22 Days on average.
| IVV | TEM | |
|---|---|---|
Market Cap | $899.63B | $12.77B |
Volume | 3,643,926 | 8,980,490 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $782.58 | $99.28 |
52-Week Low | $634.93 | $41.55 |
Typical Hold Time | 46 Days | 22 Days |
Enterprise Value | — | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $780.60, down 0.25% on the day. Technical indicators show a bullish trend with moving averages strongly positive, though RSI suggests potential overbought conditions near-term. The ETF remains a core holding for broad US equity exposure, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment is mixed as valuations attract scrutiny despite index strength.
Outlook remains constructive given the S&P 500's earnings momentum and historical seasonal trends favoring year-end rallies. Key risks include potential profit growth deceleration to 15% in 2027 and concentration in top holdings. The ETF offers diversified exposure to large-cap US equities, with the current level near pivot point support providing a strategic entry zone for long-term investors.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
